Thymopoietin, a potent antagonist at nicotinic receptors in C2 muscle cell cultures.
Recent work has shown that thymopoietin, a polypeptide with actions in the immune and nervous systems, potently binds to the alpha-bungarotoxin (alpha-BGT) receptor. The present study was done to characterize the interaction of thymopoietin at the nicotinic alpha-BGT binding site in cultured muscle cells and to correlate these findings with the effects of the polypeptide on nicotinic receptor-mediated function. Inhibition studies showed that thymopoietin potently inhibited 125I-alpha-BGT binding in C2 muscle cells in culture, with an IC50 of 1.1 nM, a value similar to that for alpha-BGT. Thymopoietin bound to the alpha-BGT receptor in the cells in culture relatively slowly; at 10(-8) M thymopoietin, maximal inhibition occurred after 45 to 75 min of exposure to the polypeptide. Dissociation of thymopoietin from the receptor exhibited a much longer time course; recovery of alpha-BGT binding to control values after exposure to 10(-8) M thymopoietin occurred approximately 16 hr after removal of the polypeptide. The effects of thymopoietin on 125I-alpha-BGT binding correlated well with those on nicotinic function. Thymopoietin potently inhibited nicotinic receptor-mediated 22Na uptake in muscle cells in culture, with an IC50 of 2 nM. This effect was dependent on the length of the preincubation period with thymopoietin, with maximal inhibition occurring after 60 min of exposure to the polypeptide. Recovery of the functional response after thymopoietin (10(-8) M) exposure required about 16 hr. The mode of inhibition of receptor-mediated ion flux by thymopoietin was similar to that observed with alpha-BGT but distinct from that obtained with d-tubocurarine and gallamine. To conclude, thymopoietin, a thymic polypeptide associated with the immune system, potently inhibited both 125I-alpha-BGT binding and nicotinic receptor-mediated function in C2 muscle cells. These findings may have implications for myasthenia gravis and/or other neuromuscular disorders.
Quik
M
M
Department of Pharmacology, McGill University, Montreal, Quebec, Canada.
el-Bizri
H
H
Audhya
T
T
Goldstein
G
G
D000818:Animals; D002038:Bungarotoxins / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D005703:Gallamine Triethiodide / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D010276:Parasympatholytics; D011485:Protein Binding; D011978:Receptors, Nicotinic / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013946:Thymopoietins / Q000494:pharmacology*; D014403:Tubocurarine / Q000494:pharmacology
D002038:Bungarotoxins; D018733:Nicotinic Antagonists; D010276:Parasympatholytics; D011978:Receptors, Nicotinic; D013946:Thymopoietins; D002217:Carbachol; D012964:Sodium; D005703:Gallamine Triethiodide; D014403:Tubocurarine